Ars Pharma
San Diego, US · Founded 2015 · 4 known investors
Find your way into Ars Pharma
358 people in our graph share verified history with the Ars Pharma team — schools, employers, funds. One of them is your warm intro.
Mark Siegelunlockedknows Richard Lowenthal · together at Massachusetts Institute of Technology (overlapped)
×2knows the team · via University of San Diego
×5knows the team · via Massachusetts Institute of Technology
×3knows the team · via Florida State University
knows the team · via Food and Drug Administration
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies. It serves patients with allergies and their caregivers.
Founders & leadership
Ars Pharma was founded in 2015 by Richard Lowenthal.
RL
Richard LowenthalinFounderRichard Lowenthal is founder and executive officer of ARS Pharmaceuticals, a biopharmaceutical company developing intranasal therapies for severe allergic reactions. He brings over 30 years of experience in pharmaceutical and biotechnology development across regulatory, quality, and strategic roles at companies including Janssen, Maxim Pharmaceuticals, and Cadence Pharmaceuticals, as well as prior service as a drug reviewer at the FDA.
PS
Pratik ShahNamed on SEC filing
Board
JL
Jonathan LeffBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$63M disclosed across 2 rounds · 2018–2021
▶$55MraisedSep 2021 · 8 investors · PharmaceuticalsRule 506(b)
▶$55MraisedSep 2021 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rajeev DadooDirector
- Peter KolchinskyDirector
- Mike KellyDirector
- Brent SaundersDirector
- Richard LowenthalExecutive Officer, Director
- Dana McGowanExecutive Officer
- Pratik ShahDirector
- Jonathan LeffDirector
- Phil SchneiderDirector
- Offering amount
- $55M
- Amount sold
- $55M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedOct 2018 · 2 investors · PharmaceuticalsRule 506(b)
▶$8MraisedOct 2018 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan LeffDirector
- Richard LowenthalExecutive Officer, Director
- Pratik ShahDirector
- Offering amount
- $20M
- Amount sold
- $8M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
ARS Pharmaceuticals Q2 2026 revenue jumps, loss widens | SPRY Quarterly Report (10-Q)stocktitan.net · Aug 2026
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rightsbarchart.com · Aug 2026
Shareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action | Press Releases | mycarrollcountynews.commycarrollcountynews.com · Aug 2026Frequently asked questions
- What does Ars Pharma do?
- ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies. It serves patients with allergies and their caregivers.
- Who founded Ars Pharma?
- Ars Pharma was founded by Richard Lowenthal in 2015.
- Who are Ars Pharma's investors?
- Ars Pharma's investors include Nextech Invest, OrbiMed, RA Capital, SR One Capital Management.
- How much funding has Ars Pharma raised?
- Ars Pharma has disclosed $63M raised across 2 rounds.
- Where is Ars Pharma headquartered?
- Ars Pharma is headquartered in San Diego, US.